S. Arroyo[REV NEUROL 2000;31:728-732]PMID: 12497347DOI: https://doi.org/10.33588/rn.3108.2000383OPEN ACCESS
Volumen 31 |
Number 08 |
Nº of views of the article 5.585 |
Nº of PDF downloads 73 |
Article publication date 16/10/2000
OBJECTIVE. Observational studies are necessary for evaluation of the efficacy and safety of the new antiepileptic drugs. Unlike blind, randomised studies, observational studies are carried out in populations of less resistant patients in normal clinical practice. Therefore these trials give valuable information regarding the efficacy and safety of antiepileptic drugs.
PATIENTS AND METHODS A multicentre trial was carried out in Spain in which patients with partial epilepsy treated with one or more antiepileptic drugs were also given tiagabine. Tiagabine was started at a dose of 5 mg per day and increased weekly by 5 mg until the dose considered suitable or a maximum of 70 mg per day was reached. Data were collected on the aetiology of the seizures, their frequency and type and the presence of sideeffects. The study was planned to take place over one year, but this paper is being written after six months followup.
RESULTS We studied 645 patients with an average age of 35.4 years. The average duration of their epilepsy was 18.3 years and 76.6% of patients had previously received three or more antiepileptic drugs. The average dose of tiagabine reached during the maintenance period was 32.6 mg/day. After six months of treatment 29.4% of the patients had had no seizures during the last three months of the trial and 67% of the population had a reduction in seizures of over 50%. Some form of sideeffect was seen in 52.4% of the patients during the study period. The commonest of these was somnolence (28.2% of the patients) but fainting (23.4%) and difficulty in paying attention/concentration were seen less frequently (15%). In most cases the sideeffects were transient or slight (tolerable). No patient had nonconvulsive illness. During the study tiagabine was stopped in 166 patients (25.7% of the total) due to lack of efficacy or intolerance. CONCLUSION. Tiagabine is effective, well tolerated addon therapy in patients with partial epilepsy.
KeywordsAnticonvulsantAntiepileptic drugsEpilepsyPartial seizuresTiagabineCategoriesEpilepsias y síndromes epilépticos
FULL TEXT(solo disponible en lengua castellana / Only available in Spanish)
Si ya es un usuario registrado en Neurologia, introduzca sus datos de inicio de sesión.
Rellene los campos para registrarse en Neurologia.com y acceder a todos nuestros artículos de forma gratuita
¿Olvidó su contraseña? Introduzca su correo electrónico y le haremos llegar una nueva
Estimado usuario de Revista de Neurología,
Debido a la reciente fusión por absorción de VIGUERA EDITORES, S.L.U., la entidad gestora de las publicaciones de Viguera Editores, entre ellas, Revista de Neurología, por EVIDENZE HEALTH ESPAÑA, S.L.U., una de las sociedades también pertenecientes al Grupo Evidenze, y con la finalidad de que Usted pueda seguir disfrutando de los contenidos y distintos boletines a los que está suscrito en la página web de neurologia.com, es imprescindible que revise la nueva política de privacidad y nos confirme la autorización de la cesión de sus datos.
Lamentamos informarle que en caso de no disponer de su consentimiento, a partir del día 28 de octubre no podrá acceder a la web de neurologia.com
Para dar su consentimiento a seguir recibiendo la revista y los boletines de neurologia.com vía correo electrónico y confirmar la aceptación de la nueva política de privacidad, así como la cesión de sus datos a Evidenze Health España S.L.U., el resto de las entidades del Grupo Evidenze y sus partners y colaboradores comerciales, incluyendo la posibilidad de llevar a cabo transferencias internacionales a colaboradores extranjeros, pulse en el siguiente enlace:
OPEN ACCESS
